<DOC>
	<DOCNO>NCT01446237</DOCNO>
	<brief_summary>This study conduct obtain safety , efficacy , satisfaction data combination topical Benzoyl Peroxide ( BPO ) 2.5 % topical keratolytic agent Salicylic Acid ( SA ) 0.5 % treatment moderate severe acne . Subjects moderate severe acne ask apply commercially available , over-the-counter product Foam Deep Cleanser ( 2.5 % BPO ) , Foam Advanced Acne Treatment ( 2.5 % BPO ) , Foam Rejuvenating Toner ( 0.5 % SA ) daily 12 week . No control group reference treatment include .</brief_summary>
	<brief_title>U0289-405 : An Open-Label , 12-Week Study Evaluate Efficacy Safety Acne System ( Benzoyl Peroxide 2.5 % , Salicylic Acid 0.5 % ) Subjects With Acne</brief_title>
	<detailed_description>This open-label , multicenter , study conduct obtain safety , efficacy , satisfaction data Acne System ( Benzoyl Peroxide 2.5 % , Salicylic Acid 0.5 % ) , include Foam Deep Cleanser ( 2.5 % Benzoyl Peroxide ) Foam Advanced Acne Treatment ( 2.5 % Benzoyl Peroxide ) Foam Rejuvenating Toner ( 0.5 % Salicylic Acid ) , treatment moderate severe acne . Approximately 120 male female subject age 12-35 year , inclusive , moderate severe acne assess Investigator 's Global Assessment ( ISGA ) lesion count expect enrolled . Subjects instruct use 3 study product part complete acne treatment system ; reference therapy control group include . Subjects instruct apply Foam Deep Cleanser ( 2.5 % Benzoyl Peroxide ) Foam Advnced Acne Treatment ( 2.5 % Benzoyl Peroxide ) face morning Foam Deep Cleanser ( 2.5 % Benzoyl Peroxide ) Foam Rejuvenating Toner ( 0.5 % Salicylic Acid ) even application period 12 week .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<mesh_term>Salicylic Acid</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<criteria>Capable understand willing provide sign dated write voluntary inform consent ( local national authorization requirement ) protocolspecific procedure perform . Male female age 12 35 year , inclusive time consent . ISGA score 3 4 Baseline . Lesion count meeting follow criterion : A : A minimum 25 50 facial inflammatory lesion ( papule pustule ) , exclude nasal lesion . B : A minimum 20 100 facial noninflammatory lesion ( open close comedo ) , exclude nasal lesion . C : No 3 facial nodular lesion ( &lt; 5mm ) , cystic lesion . Ability willingness follow study procedure , attend schedule visit , successfully complete study . Negative urine pregnancy test female childbearing potential . Sexually active female childbearing potential participating study must agree use medically acceptable method contraception receive protocolassigned product . Female pregnant , try become pregnant , breast feeding . History lupus , dermatomyositis , rosacea , seborrheic dermatitis , beard folliculitis , polycystic ovary syndrome , hirsutism , perioral dermatitis . ( Subjects Seborrheic dermatitis may enrol condition inactive least 1 year and/or affect face . ) Use topical antibiotic face within past 2 week systemic antibiotic acne treatment within past 4 week . Concurrent use medication know photosensitizers ( eg , thiazide , tetracycline , fluoroquinolones , phenothiazine , sulfonamide ) possibility augment photosensitivity . Use topical corticosteroid face within past 2 week systemic corticosteroid within past 4 week . Use inhale , intraarticular , intralesional steroid facial acne acceptable . Use systemic retinoids ( eg , isotretinoin ) within past 6 month . Treatment estrogens , include oral , implanted , injected , topical contraceptive , androgen , antiandrogenic agent 12 week fewer immediately prior study enrollment . Subjects treat estrogen , describe , androgen , antiandrogenic agent 12 consecutive week prior study enrollment allow enroll long expect change dose drug , discontinue use study indicate treatment acne vulgaris . Male facial hair could interfere study assessment . Use topical antiacne medication ( eg , BPO , retinoids , azelaic acid , resorcinol , sulfur derivative , SA , alpha beta hydroxy acid , antioxidant , antiwrinkle , antimicrobial , glycolic acid , abradant ) within past 2 week . Use superficial facial procedure , natural/herbal product within past 4 week . Concomitant use medication report exacerbate acne may impact efficacy assessment . Facial procedure ( eg , blue light , chemical laser peel , microdermabrasion ) perform aesthetician , beautician , physician , nurse , practitioner within past 8 week . facial skin cancer diagnosis precede 12 month . Require desire excessive prolonged exposure ultraviolet light ( eg , sunlight tan bed ) study . Dermatological disorder opinion investigator may interfere accurate evaluation subject 's facial appearance . Any major illness within 4 week study enrollment . Previous use study product . Use investigational drug procedure within past 4 week currently participate another clinical study . Known hypersensitivity previous allergic reaction active component study product . Any condition , judgement investigator , would put subject unacceptable risk participation study . Current drug alcohol abuse . ( Drug screening require . ) Considered unable unlikely attend necessary visit . Employee investigator , clinical research organization , Stiefel , GSK company , GlaxoSmithKline ( GSK ) involve study , immediate family member ( eg , partner , offspring , parent , sibling sibling 's offspring ) employee involve study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>